2020
DOI: 10.1002/ccr3.3302
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature

Abstract: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
9
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(9 citation statements)
references
References 32 publications
0
9
0
Order By: Relevance
“…Other authors postulated that the M-protein acts as an antibody which directly stimulates fibroblast proliferation and mucin deposition. 3 Various treatments with inconsistent results have been described. 1,2 Systemic corticosteroids seem to be mainly a symptomatic treatment.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Other authors postulated that the M-protein acts as an antibody which directly stimulates fibroblast proliferation and mucin deposition. 3 Various treatments with inconsistent results have been described. 1,2 Systemic corticosteroids seem to be mainly a symptomatic treatment.…”
Section: Discussionmentioning
confidence: 99%
“…6 Lenalidomide stimulates NK-cell activity and increases IL-2 production, enhancing T-cell activity. 7 It has been used in various studies in the treatment of SM, in association with dexamethasone, IVIG or bortezomib, with daily dosages from 10 to 15 mg. 3,7,8 No treatment failures have been described. Duration of response has been variable, but no relapses were noted.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…It is commonly used to treat relapsed/refractory multiple myeloma. Its use in SMX has been reported in 8 patients who differed in terms of clinical history, presentation and outcome, as well as treatment regimens (4)(5)(6)(7)(8)(9)(10)(11)(12)(13).…”
Section: Discussionmentioning
confidence: 99%
“…In context of dermato-neuro syndrome, the combination of IVIg and systemic corticosteroids are the treatment of choice according to European guidelines [ 115 ]. Lenalidomide [ 116 ] or bortezomib therapy [ 117 119 ] may achieve rapid improvement of cutaneous and systemic manifestations of scleromyxedema [ 120 ]. However, more studies addressing these issues are warranted.…”
Section: Group IImentioning
confidence: 99%